Healthcare
Fennec Pharmaceuticals Inc.(FENC)
Live Price
Offline$9.06
+0.89% today
1Y Change
+25.60%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $210.00M
- Revenue Growth
- -4.4%
- EPS Growth
- -2150.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fennec Pharmaceuticals Inc. (FENC) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $9.06 and up 25.6% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -4.4%, EPS growth of -2150.0%, a dividend yield of 0.0%. What stands out right now is revenue -4.4%, EPS -2150.0%, free cash flow -146.2% with operating margin -15.1% and ROIC -11.4%. Valuation sits in the middle of the pack at price/sales 4.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines FENC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-4.4% vs +7.6% peer median
Operating Margin
Below sector median
-15.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -4.4% and EPS is at -2150.0%, with operating margin around -15.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +14.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -3.7% | +38.8% | +23.8% |
2026 Mar 24, 2026 | -466.7% | +2.5% | +2.2% | +11.0% |
2025 Nov 13, 2025 | +75.0% | +2.2% | +2.0% | -1.8% |
Benchmark Edge
FENC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FENC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FENC Max Drawdown
-41.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FENC and SPY.
Company Overview
Fennec Pharmaceuticals Inc.
NASDAQ Capital Market
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- Leadership
- Jeffrey S. Hackman
- IPO Date
- Sep 15, 2017
- Employees
- 32
- Street Address
- 68 TW Alexander Drive
- Mailing
- Research Triangle Park, NC, 27709
- Region
- Research Triangle Park, NC, US
- Reporting Currency
- USD
- Investor Line
- 919 636 4530
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.6
- Price/Book
- 6.4
Growth
- Revenue
- -4.4%
- EPS
- -2150.0%
- Free Cash Flow
- -146.2%
Profitability
- Gross Margin
- 91.5%
- Operating Margin
- -15.1%
- Net Margin
- -22.7%
- ROE
- -236.4%
- ROIC
- -11.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 6.34
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.